The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8

被引：0
|
作者：
Jakesz, R [1 ]
Gnant, M [1 ]
Greil, R [1 ]
Tausch, C [1 ]
Samonigg, H [1 ]
Kwasny, W [1 ]
Kubista, E [1 ]
Stierer, M [1 ]
Luschin, G [1 ]
Mittlboeck, M [1 ]
机构：
[1] Vienna Med Sch, Vienna, Austria
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S10 / S10
页数：1
相关论文
共 50 条
  • [21] Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E) or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer. The FATA-GIM3 trial
    De Placido, S.
    Gallo, C.
    De Laurentiis, M.
    Bisagni, G.
    Arpino, G.
    Sarobba, M. G.
    Riccardi, F.
    Russo, A.
    Del Mastro, L.
    Cogoni, A.
    Cognetti, F.
    Gori, S.
    Frassoldati, A.
    Amoroso, D.
    Laudadio, L.
    Moscetti, L.
    Montemurro, F.
    Nuzzo, F.
    Carlini, P.
    Perrone, F.
    ANNALS OF ONCOLOGY, 2017, 28 : 1 - 1
  • [22] Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12
    Gnant, M.
    Mlineritsch, B.
    Schippinger, W.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Menzel, C.
    Jakesz, R.
    Kubista, E.
    Marth, C.
    Greil, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [23] Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5
    Jakesz, R
    Hausmaninger, H
    Samonigg, H
    Kubista, E
    Depisch, D
    Fridrik, M
    Stierer, M
    Gnant, M
    Steger, G
    Kolb, R
    Jatzko, G
    Hofbauer, F
    Reiner, G
    Steindorfer, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S83 - S83
  • [24] Letrozole A Review of its Use in the Treatment of Postmenopausal Women with Hormone-Responsive Early Breast Cancer
    Keating, Gillian M.
    DRUGS, 2009, 69 (12) : 1681 - 1705
  • [25] Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
    Baum, M
    Buzdar, AU
    Cuzick, J
    Forbes, J
    Houghton, J
    Klijn, JGM
    Sahmoud, T
    LANCET, 2002, 359 (9324): : 2131 - 2139
  • [26] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
    Karnon, Jonathan
    Delea, Thomas
    Barghout, Vicki
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 9 (02): : 171 - 183
  • [27] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
    Jonathan Karnon
    Thomas Delea
    Vicki Barghout
    The European Journal of Health Economics, 2008, 9
  • [28] LetrozoleA Review of its Use in the Treatment of Postmenopausal Women with Hormone-Responsive Early Breast Cancer
    Gillian M. Keating
    Drugs, 2009, 69 : 1681 - 1705
  • [29] 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer-efficacy overview
    Buzdar, AU
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2003, 86 (3-5): : 399 - 403
  • [30] Health economic evaluation based on the 5-year completed treatment analysis of the ATAC trial comparing anastrozole versus tamoxifen in adjuvant treatment of postmenopausal hormone receptor positive early breast cancer
    Moeremans, K
    Annemans, L
    VALUE IN HEALTH, 2005, 8 (06) : A21 - A22
12345